Triple imaging technique aims to sharpen prostate cancer detection
NCT ID NCT02971995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new way to guide prostate biopsies by combining three imaging methods: a PET scan using a special tracer (fluorocholine), multiparametric MRI, and 3D ultrasound. The goal was to see if this triple approach could more accurately target suspicious areas in the prostate. The study enrolled 31 men with suspected prostate cancer, but was terminated early, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fluorocholine (tracer for PET scan)
- What this could lead to
- If successful, this approach could make prostate cancer biopsies more precise, reducing false negatives and unnecessary procedures.
- What could go wrong
- The study was terminated early with only 31 participants, so results are limited. The technique may not be widely available or better than standard methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FLUOROCHOLINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New scan could replace risky vein test for Hormone-Driven high blood pressure
- New imaging agent could sharpen cancer detection
- Could a fatty liver fuel Alzheimer's? new scan aims to find out
- New scan could reveal hidden cancers in PD-L1 patients
- New PET tracer aims to spot Huntington's protein clumps in living brains
- PET-CT scans may help spot hidden lung cancer spread